Taylor Wessing has been named as the recipient of "The Impact Case of the Year" award at The Managing IP EMEA Awards 2020 for its work for global generic and specialty pharmaceuticals company, Mylan.
In the Actavis v ICOS case, the firm acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).
The firm successfully defended an application by Eli Lilly for an injunction pending appeal to the Supreme Court and then represented Mylan in the Supreme Court. The judgment of the Supreme Court was handed down on 27 March 2019 and upheld the Court of Appeal's decision in Mylan's favour, allowing access to the full tadalafil market.
Matthew Royle, partner in the patents team who led the case, commented: "This award underlines the standout work we have been doing for Mylan for some years and is the second year in a row that we have been recognised for this work with an award for Impact Case of the Year. The case also underlines our expertise in life sciences and shows the breadth of skill we have across our patent team. I am hugely proud of this achievement and look forward to advising Mylan for years to come."
The Managing IP awards programme recognises remarkable achievements and developments in the past 12 months. They are the result of MIP's extensive World IP Survey, which pinpoints the firms, individuals and corporations excelling in IP globally.
In 2019, Taylor Wessing was named European Trade Mark Firm of the Year and recognised for two Impact Cases of the Year – Warner-Lambert v Mylan (pregabalin) and Teva v Gilead (Truvada).
The team was led by partner Matthew Royle with support from patent senior associate Amanda Ebbutt and patent associate Josie Miller.
